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Abstract
Post-translational protein modifications such as acetylation have significant regulatory roles in metabolic processes, but
their relationship to both variation in gene expression and DNA sequence is unclear. We address this question in the Goto-
Kakizaki (GK) rat inbred strain, a model of polygenic type 2 diabetes. Expression of the NAD-dependent deacetylase Sirtuin-3
is down-regulated in GK rats compared to normoglycemic Brown Norway (BN) rats. We show first that a promoter SNP
causes down-regulation of Sirtuin-3 expression in GK rats. We then use mass-spectrometry to identify proteome-wide
differential lysine acetylation of putative Sirtuin-3 protein targets in livers of GK and BN rats. These include many proteins in
pathways connected to diabetes and metabolic syndrome. We finally sequence GK and BN liver transcriptomes and find that
mRNA expression of these targets does not differ significantly between GK and BN rats, in contrast to other components of
the same pathways. We conclude that physiological differences between GK and BN rats are mediated by a combination of
differential protein acetylation and gene transcription and that genetic variation can modulate acetylation independently of
expression.
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Introduction
Post-translational modification (PTM) of proteins is one means
by which an organism can alter protein function independently of
transcription and translation. There are over 400 characterised
PTMs, including phosphorylation, acetylation, methylation, ubi-
quitination and SUMOylation. In this study, we focus on protein
acetylation, which is regulated by complex mechanisms involving
families of acetyltransferases and deacetylases. Acetylation of
enzymes may affect their activity, and is a mechanism used by cells
to make metabolic adaptations, possibly through the coordination
of pathways such as glycolysis, gluconeogenesis, citrate cycle, fatty
acid metabolism, urea cycle, and glycogen metabolism [1]. Many
of the essential enzymes required for metabolite processing in liver
are acetylated [2]. As a consequence, variation in protein
acetylation is expected to affect diseases such as diabetes and the
metabolic syndrome (Reaven’s syndrome).
Animal models of diabetes can reveal causal relationships
between altered protein acetylation and impaired glucose homeo-
stasis. The Goto-Kakizaki (GK) rat is an established model of
spontaneous non-obese Type 2 diabetes, which has elevated blood
glucose and peripheral insulin resistance similar to human Type 2
diabetes [3]. The genetic basis of metabolic and hormonal
anomalies in the GK rat has been mapped in crosses between
GK and non-diabetic Brown Norway (BN) rats which identified
quantitative trait loci (QTL) linked to diabetes-related phenotypes
such as glucose intolerance [4]. The GK rat is also a model for the
metabolic syndrome, because it exhibits traits of salt-induced
hypertension, increased adiposity, glucose intolerance, and hyper-
lipidemia [5–8].
Previous genome-wide liver transcriptome analyses in rat strains
[9] identified significantly down-regulated expression of the NAD-
dependent deacetylase sirtuin 3 (Sirt3) in GK compared to BN rats.
Sirtuins influence insulin sensitivity and energy homeostasis and
possibly ageing. There is controversy over their role in ageing [10],
but it is known that they mediate metabolic adaptation to stress
and changes in nutrition [11].
The transcriptional difference between GK and BN was
confirmed in a further microarray study [6] of a congenic rat
strain carrying a large section (170 Mb) of GK chromosome 1
associated with glucose intolerance, where Sirt3 is localised, on a
BN genetic background (1consomic). GK alleles in this region are
associated with lower Sirt3 expression (p = 0.0030). Sirt3 is likely to
affect metabolism and may account for the observed effect because
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it is a key regulator of mitochondrial protein acetylation levels
[12].
Due to the potential importance of differential expression of
Sirt3 between BN and GK rats, we undertook a series of
experiments to first validate and then fine-map the difference in
Sirt3 transcript levels to discover the cause of this variation, and
finally to explore the effects of lower Sirt3 deacetylase activity on
protein acetylation in liver, and determine whether differences in
lysine acetylation of metabolic enzymes sheds light on the
pathophysiology of the GK rat. We identify alterations in liver
protein acetylation and gene transcription that may contribute to
physiological differences between GK and BN rats.
Results
Transcription regulation of Sirt3 in congenic strains of the
GK rat
We performed genome-wide gene expression analysis using
Illumina expression microarrays, on white adipose tissue, kidney,
skeletal muscle, liver and brown adipose tissue (BAT) from BN and
1consomic rats, and found 1.6-fold higher transcript levels of Sirt3
in BAT from BN rats compared to 1consomic rats (p = 6.761025),
and similar results in liver, consistent with our earlier finding
obtained with Affymetrix arrays in liver from the same congenic
and control rats [9]. Sirt3 is the tenth most significantly
differentially expressed gene (DEG) out of 92 DEG in the
1consomic interval in BAT, and twelfth most differentially
expressed gene in liver (out of 100 DEG). The difference in Sirt3
expression appears to be specific to liver and BAT, because it was
not present in white adipose, kidney or skeletal muscle. We
performed qRT-PCR in order to validate these differences in liver
and BAT from BN and 1consomic rats. Expression of Sirt3 was
significantly lower in both tissues from 1consomic compared to BN
(p,0.05) (Figure 1A).
To fine-map this variation, we used qRT-PCR to compare Sirt3
transcription in BAT from three BN.GK congenic strains of rat
chromosome 1 containing either the GK allele of Sirt3 (strains 1h
and 1o) with BN or the BN allele of Sirt3 (strain 1b). Figure 1B,
right, illustrates these congenic strains, and shows that compared
to BN and congenic 1b, Sirt3 expression was lower (p,2.061024)
in strains 1h and 1o. These results confirm that GK alleles nearby
Sirt3 down-regulate its transcription in cis.
Identification and functional analysis of Sirt3
polymorphisms in the GK rat
To identify the cis-acting variants affecting Sirt3 transcription,
we compared the sequences of the Sirt3 gene, including its
promoter, in GK and BN in the interval 1:201019865-201045697.
We detected 64 intronic SNPs, 3 intronic insertions, 3 intronic
deletions, one known synonymous coding SNP (rs13449840), and
one SNP in the 59-UTR, which was within the Sirt3 promoter
(1:201044229_C/T). We investigated the consequences of segre-
gating polymorphisms using the Variant Effect Predictor [13])
(Table S1) but no obviously functional coding variants were found.
The 646 bp Sirt3 promoter is bi-directional, and lies between
the transcriptional start site (TSS) of Sirt3 and the TSS of a
neighboring gene encoding the proteasome non-ATPase regula-
tory subunit 13 (Psmd13) (Figure 2A) [14]. Expression of Psmd13
was not altered in liver and BAT of GK and BN rat. The Sirt3
promoter SNP occurs within a predicted binding site for the
estrogen-related receptor response element (ERRE) transcription
factor, which is known to activate Sirt3 transcription in the mouse
[15]. In order to test whether the variant affected function of the
ERRE, we cloned both the BN and GK alleles of the promoter
sequence into luciferase reporter construct pGL3-basic. No
difference in luciferase activity was observed when HEK293T
kidney cells were transfected at two concentrations with the GK
promoter compared to BN control (Figure S1). However, when
transfected into Hep3B hepatocyte cells, luciferase activity driven
by the GK promoter at the higher level of transfection was
significantly less than that of BN (p,0.05) (Figure 2B). We
conclude that the GK promoter variant in Sirt3 is the likely cause
of the cis-regulated transcriptional downregulation of the GK
allele, and that this effect is tissue-specific.
RNA-sequencing
We sequenced mRNA from the liver and BAT of GK and BN
rats, and identified differentially expressed transcripts in each
tissue (Tables S2 and S3). RNA-sequencing re-confirmed that Sirt3
is down-regulated in both BAT (GK 47% lower than BN) and liver
(37% lower) from GK rats compared to BN. KEGG pathway
enrichment analysis was then performed (Tables S4 and S5). In
BAT, the most significantly over-represented pathways that
differentiated GK and BN rats were ‘‘Metabolic pathways’’
Figure 1. Validation of Sirt3 transcript levels. QRT-PCR of Sirt3 levels (A) comparing BN control rat and congenic strain 1consomic (which has GK
chromosome 1 on a BN genetic background), in liver (blue) and BAT (green); (B) left, comparing BAT from BN and three congenic strains, two carrying
GK allele of Sirt3 (1o and 1h), and one with BN allele of Sirt3 (1b); (C) diagram of BN.GK chromosome 1 congenic strains used, with maroon bars
representing region of GK chromosome 1 introgressed onto BN background. (Genomic location of Sirt3 is indicated.) Results are corrected for
expression of housekeeping gene 36B4.
doi:10.1371/journal.pone.0094555.g001
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(p = 3.08610213) and ‘‘Oxidative phosphorylation’’ (p = 1.636
1029). Digestion and absorption of protein and fat are also over-
represented in BAT, as well as fatty acid metabolism and PPAR
signaling pathway. In liver, KEGG analysis again highlights
‘‘Metabolic pathways’’ as the most significantly over-represented
pathway amongst the differentially expressed genes
(p = 8.41610214). Cytochrome P450 metabolism, PPAR signaling
and steroid hormone biosynthesis are among the top five
significantly over-represented pathways in liver. Because Sirt3 is
a target of PPARG-coactivator1-alpha, and therefore involved in
PPAR-gamma signaling, it is not surprising that PPAR signaling is
affected [15].
Proteome-wide analysis of liver protein acetylation
Since Sirt3 is the major deacetylase enzyme in mitochondria, we
reasoned that lower levels of Sirt3 in GK liver would increase
lysine-acetylation of proteins. Therefore, we determined global
liver protein acetylation in GK and BN rats. First, in order to
enrich for acetylated proteins, an equal amount of liver protein
extract from GK and BN rats was digested with trypsin, then
subjected to immunoprecipitation using pan-acetyllysine antibod-
ies. These enriched peptides were analysed by liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS). The 89 differen-
tially acetylated peptides we identified with .95% confidence are
listed in Table S6, and examples are shown in Figure S2.
Unfortunately, we could not determine global lysine acetylation in
BAT, possibly due to insufficient tissue.
As the measurement of acetylated peptides does not distinguish
between differing levels of protein and differing levels of
acetylation, we used our transcriptomic data to test if the
acetylation differences were correlated with variable gene expres-
sion, which we measured on the level of gene transcription.
Absence of differential gene expression would suggest that
observed acetylation differences are due to differential protein
acetylation. Transcript measurements for each lysine-acetylated
protein are given in Table S6. Transcripts for 28% of the
acetylated proteins are differentially expressed at FDR p,0.05,
but for 91% of the peptides, there is either no change in transcript
level, or it is in the opposite direction to the change in acetylation.
When fold-change of acetylation is plotted against fold-change of
RNA-seq, no correlation is observed (Figure 3). Therefore, most of
the differences measured by mass-spectrometry are likely to be due
to varying acetylation levels rather than amount of protein.
Eighteen genes encoding known acetylated proteins have signif-
icantly different gene expression between BN and GK or
1consomic liver (see Table 1), but none were significantly
differentially acetylated (malate dehydrogenase 1, but not malate
dehydrogenase 2, is differentially acetylated). We do not know
whether the proteins in Table 1 are not acetylated in GK or BN
rat liver, or whether they are acetylated but below our level of
detection.
Most of the differentially acetylated peptides between GK and
BN liver (Table S6, Figure S2), are enzymes in key metabolic
pathways, as listed below. Thirty-six of the 89 proteins listed were
also found to be acetylated in a study of Sirt3-knockout mice,
providing evidence that they are targets of Sirt3 [16]. Note that
proteins annotated ‘‘BN only’’ or ‘‘GK only’’ might still be
acetylated below the level of detection for the experimental
approach used.
(i) Glycolysis and gluconeogenesis. Peptides from glycer-
aldehyde 3-phosphate dehydrogenase (Gapdh) were acetylated
between 2.3- and 2.7-fold more in GK than BN liver. One
acetylated peptide of dihydrolipoamide dehydrogenase (Dld), a
component of pyruvate dehydrogenase complex, is only detected
in GK liver, and another Dld derived peptide is about 10% less
acetylated in GK than BN. Acetylated phosphoglycerate kinase 2
was detected in BN only. Other acetylated proteins with the
KEGG term glycolysis/gluconeogenesis include alcohol dehydro-
genase (Adh), with one peptide 2-fold more acetylated in GK, and
one slightly less in GK than BN, and lactate dehydrogenase, where
an LdhC peptide is acetylated in GK only and an LdhA peptide
acetylated in BN only.
(ii) TCA cycle. Acetylation of aconitate hydrolase (Aco) is 2-
fold higher in GK liver than in BN. Dihydrolipoyllysine-residue
succinyltransferase (Dlst) and one peptide of dihydrolipoamide
dehydrogenase (Dld), which are components of the a-ketoglutarate
dehydrogenase complex in TCA cycle, are only acetylated in GK
liver. Succinyl-CoA synthetase alpha subunit (Suclg1) is 2.6-fold
more acetylated in GK than BN livers. Both succinate dehydro-
genase (Sdh), a known target of Sirt3, and fumarate hydratase, were
only acetylated in GK. Malate dehydrogenase 1 (Mdh1) was only
acetylated in BN liver (this is the cytosolic isoform involved in the
malate-aspartate shuttle). Peptides from different subunits of ATP
synthase in oxidative phosphorylation are also acetylated: ATP
synthase subunit A is only acetylated in GK, ATP synthase subunit
B is acetylated in both GK and BN, and ATP synthase subunit D
is twice as acetylated in GK as BN.
(iii) Pentose phosphate pathway (hexose monophosphate
shunt). Components of this pathway, which is the major source
of NADPH required for anabolic processes, were acetylated. For
example, UDP-glucose 6-dehydrogenase was only acetylated in
Figure 2. Sirt3 promoter variant and luciferase assay. (A) Bidirectional promoter of Sirt3 and Psmd13. One single nucleotide polymorphism
(1:201044229_C/T) was identified when comparing sequence of GK promoter with BN. (B) Luciferase reporter assay results for transfection of
hepatoma cell line. BN or GK allele of Sirt3 promoter was cloned into pGL3-basic vector upstream of luciferase gene, and transfected into Hep3B cells
at two levels, 0.1 and 0.4 ug/well. Results are corrected for transfection efficiency by co-transfection with beta-galactosidase vector, and represent
two-three independent transfections, which were run in triplicate wells.
doi:10.1371/journal.pone.0094555.g002
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GK liver. Transketolase (Tkt) was 2.6-fold more acetylated in GK
than BN liver.
(iv) Fatty acid metabolism. These pathways include acetyl-
CoA acyltransferase (Acaa2), an enzyme in fatty acid beta-
oxidation and elongation, which has 2 acetylated peptides that
are only detected in GK liver. One peptide of mitochondrial
acetyl-CoA acetyltransferase Acat1 is more highly acetylated in GK
rat liver than in BN, but other peptides from Acat1 and a peptide
from cytosolic Acat2 are only acetylated in BN liver. Mitochondrial
medium-chain acyl-CoA dehydrogenase (Acadm) and enoyl-CoA
delta isomerase 1 (Eci1) are only acetylated in GK liver. Echs1
(enoyl-CoA hydratase/3-ketoacyl thiolase 1, mitochondrial) is
acetylated about equally in GK and BN. Several peptides of fatty
acid-binding protein, important in fat transport and PPAR
Figure 3. Scatter-plot of log fold-change of lysine acetylation and fold-change of RNA-sequencing. Each point represents one protein/
transcript. y-axis: log2 of fold change in protein acetylation between GK and BN rats. x-axis: log2 of fold-change in mRNA sequence counts between
GK and BN rats.
doi:10.1371/journal.pone.0094555.g003
Table 1. Illumina liver transcripts significantly differentially expressed between GK and BN or 1Consomic strain rats.
Gene Symbol Description
GK/BN log2
fold-change
GK/BN
FDR
1Cons/BN log2
fold-change
1Cons/BN
FDR
Phf20 PHD finger protein 20 0.68 0.0000 20.21 0.146
Asl argininosuccinate lyase 21.40 0.0000 0.15 0.666
Mdh2 malate dehydrogenase 2, NAD (mitochondrial) 0.41 0.0002 20.30 0.027
Spi1 spleen focus forming virus (SFFV) proviral integration oncogene spi1 0.84 0.0003 0.08 0.819
Taf5l TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor 20.59 0.0005 0.63 0.008
Ncoa1 nuclear receptor coactivator 1 20.42 0.0022 20.10 0.609
Dscc1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) 0.39 0.0044 0.26 0.152
Ctbp1 C-terminal binding protein 1 0.28 0.0047 20.20 0.145
Pole4 polymerase (DNA-directed), epsilon 4 (p12 subunit) 0.26 0.0071 0.09 0.509
Yeats4 YEATS domain containing 4 0.32 0.0097 20.09 0.621
Kat2a K(lysine) acetyltransferase 2A 0.42 0.0138 0.09 0.745
Gata2 GATA binding protein 2 20.28 0.0188 0.00 0.988
Por P450 (cytochrome) oxidoreductase 20.55 0.0347 0.16 0.695
Mbd3 methyl-CpG binding domain protein 3 0.28 0.0361 0.29 0.119
Bag6 BCL2-associated athanogene 6 20.23 0.0363 0.08 0.606
RGD1563945 similar to mKIAA0215 protein 20.14 0.1694 20.30 0.037
Bmi1 Bmi1 polycomb ring finger oncogene 0.18 0.5394 0.79 0.039
Eid1 EP300 interacting inhibitor of differentiation 1 0.02 0.9189 0.49 0.040
Gene ontology descriptions relating to protein acetylation or deacetylation are shown. Transcripts with False Discovery Rates (FDR),0.05 are in bold.
doi:10.1371/journal.pone.0094555.t001
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signaling, are acetylated, and one of these is 2.7-fold more
acetylated in BN than in GK. Diazepam binding inhibitor (Dbi),
which plays a role in acyl-CoA metabolism and mitochondrial
steroidogenesis, is 1.5-fold more acetylated in BN than GK.
(v) Amino acid metabolism. Lysine ketoglutarate reductase,
in lysine degradation, is only acetylated in GK. Similarly, aspartate
aminotransferase (Got2) is only acetylated in GK, as was choline
dehydrogenase (Chdh) and dimethylglycine dehydrogenase
(Dmgdh), which are involved in glycine, serine and threonine
metabolism, and glutamic-oxaloacetic transaminase 2 (Got2).
Formimidoyltransferase-cyclodeaminase (Ftcd), an enzyme of
histidine and one carbon metabolism, is only acetylated in BN.
Omega-amidase (Nit2), which is involved in alanine, aspartate and
glutamate metabolism, is acetylated 2-fold more in BN than in GK
liver. There are several enzymes involved in amino acid
metabolism that are acetylated, but differ less than 25% in their
acetylation between BN and GK. These include aldehyde
dehydrogenase 9A1 (Aldh9a1), which participates in degradation
of many amino acids; arginase 1, betaine-homocysteine S-
methyltransferase (Bhmt), which functions in methionine, cysteine,
glycine, serine and threonine metabolism, and S-adenosylhomo-
cysteine hydrolase (Ahcy), which is involved in cysteine and
methionine metabolism.
(vi) Purine and pyrimidine pathway. This includes aden-
osine kinase (Adk) and adenylate kinase (Ak), which are only
acetylated in GK liver. Two peptides of carbamoyl-phosphate
synthetase I (Cps1) are acetylated, one at about equal levels in BN
and GK, and one that is twice as acetylated in BN as compared to
GK. Carbamoyl-phosphate synthetase 2/aspartate transcarbamyl-
ase/dihydroorotase (Cad) is only acetylated in GK. Dihydropyr-
imidinase (Dpy) is very similar, with two acetylation sites detected,
one about equally acetylated and one that is only acetylated in BN
(Table S6).
Thus, as in other studies of protein acetylation, we find a wide
range of metabolic pathways whose enzymes are affected by this
modification. However, as lysine acetylation can either activate or
inhibit an enzyme’s activity, the direction of effect must be
determined empirically for each protein. Therefore, we cannot
predict the overall consequence of differential acetylation for the
majority of these pathways.
However, the citrate (TCA) cycle does contain enzymes for
which the effect of acetylation has been directly determined, and
by combining transcriptomic and proteomic data, we can predict
the effects on this pathway due to acetylation rather than amount
of protein. Additionally, we observe some TCA proteins that are
not acetylated are nonetheless differentially expressed, which can
also affect enzyme activity. Thus, the TCA pathway serves as a
model for integrating the transcriptome and proteome, in order to
give a more complete view of differences between the diabetic GK
and control BN rat liver (Figure 4).
Liver transcription regulation of acetyltransferases and
deacetylases
We also examined transcription patterns of genes encoding
acetyltransferases and deacetylases in our Illumina transcriptomic
data that were identified using Gene Ontology terms. We did so in
order to determine whether the differences that we measured in
lysine acetylation are part of a general trend toward altered
acetylation, or specific to the down-regulation of Sirt3 (Tables 2
and 3). Nineteen acetyltransferases and eleven deacetylases were
significantly differentially expressed between BN and GK, though
the annotation may be incomplete. For instance, Sirt3 was not
originally annotated on the Illumina array as a deacetylase.
Besides Sirt3, there are five other deacetylases that show
significantly lower transcript level in GK than BN livers: MACRO
domain containing 1 (Macrod1), amidohydrolase domain contain-
ing 2 (Amdhd2), and histone deacetylases Hdac3, Hdac5, and Hdac11
(however, the substrates of Macrod1 and Amdhd2 are not proteins).
Deacetylases that are overexpressed in GK (or 1consomic) when
compared to BN are N-deacetylase/N-sulfotransferase (Ndst1),
with target heparan sulfate (a linear polysaccharide), Phosphati-
dylinositol glycan anchor biosynthesis, class L (Pigl), with target N-
acetyl-D-glucosaminylphosphatidylinositol (a glycerophospholi-
pid), arylacetamide deacetylase (Aadac), and ataxin 3 (Atxn3).
Acetyltransferases that are significantly different between BN and
GK include enzymes that acetylate xenobiotics (Nat1, higher in
GK, and Nat2, lower in GK), metabolites (Acat3, Gnpnat1 and Crat,
higher in GK; Gnpat, lower in GK), phospholipid (Lpcat1, lower in
1consomic), and a few where targets are unknown (Taf5l, Nat8,
Nat8b). In certain cases, protein targets of the acetyltransferase
have been identified: Pafah1b1, with targets platelet-activating
factor and Plekhm1, and Sat2, with target eukaryotic initiation
factor 5A, both lower in GK; and Pafah1b3, with target platelet-
activating factor, Phf20, which targets histone; Naa20, which acts
on proteins in cell cycle progression, and Kat2a, with target PGC-1
alpha, which are higher in GK. Macrod1 is functionally related to
Sirt3, because a product of Sirt3 deacetylation reaction, O-acetyl-
ADP-ribose, is a substrate ofMacrod1 [17].Macrod1 is not known to
deacetylate proteins. Besides Sirt3, no other members of the sirtuin
family are differentially expressed in liver (Table 3).
None of the differentially expressed acetyltransferases are in the
chromosome 1 QTL linked to diabetes-related traits. Both acetyl-
Coenzyme A acetyltransferase 3 and lysophosphatidylcholine
acyltransferase 1 map to chromosome 1 but outside of the QTL
region. Of the deacetylases tested for differential transcription,
only Sirt3 and Macrod1 are within the QTL. As noted in Table S6,
40% of the acetylated proteins that we detected were also
identified in a Sirt3-knockout model, and therefore are likely to be
Sirt3 targets [16]. We conclude that, although we observe some
difference in other enzymes affecting acetylation, a significant
fraction of the changes in lysine acetylation are likely to be due to
down-regulation of Sirt3.
Discussion
In this study, we have shown how transcript level and protein
acetylation combine to control protein activity. This integrated,
systems-level approach is crucial for understanding the regulation
of complex phenotypes, including pathophysiological mechanisms
involved in type 2 diabetes and cardiometabolic diseases. In our
data, protein acetylation and gene transcription are independent
of each other (figure 3) and hence have uncorrelated effects.
We identified a SNP in the promoter of Sirt3 that is probably
responsible for the lower expression of Sirt3 in the liver of GK rats,
and for downstream variation in protein acetylation in enzymes
and pathways linked to diabetes and the metabolic syndrome. Sirt3
transcription is strongly activated by PGC-1a in combination with
ERRa in mouse muscle cells and hepatocytes [15]. It also mediates
the influence of PGC-1a on mitochondrial biogenesis and the
production of reactive oxygen species. Mouse knockouts of Sirt3
cause mitochondrial protein hyperacetylation [12]. The effect of
deacetylation by Sirt3 on enzyme activity has been measured
experimentally for 18 proteins [18,19], and for 78% of these, the
deacetylated form has higher activity. Enzymes whose activities
increase upon deacetylation include mitochondrial acetyl-CoA
synthetase (AceCS2), required for producing acetyl-CoA under
ketogenic conditions such as fasting. Sirt3 deacetylation also acti-
vates Complexes I (NDUFA9) and II (succinate dehydrogenase) of
Differential Acetylation in Diabetic Rats
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the electron transport chain, though SDH activity was reported to
be affected only in MEFs and brown adipose tissue, not liver
[10,20]. Sirt32/2 knockout mice have reduced ATP production
[21]. Other enzymes in the TCA cycle affected by deacetylation
include isocitrate dehydrogenase (deacetylation causes higher
activity) [22] and malate dehydrogenase (lower activity) [18]. Sirt3
reduces reactive oxygen species in cells by activating mitochondria
manganese superoxide dismutase 2 [23]. Mitochondrial 3-
hydroxy-3-methylglutaryl CoA synthase 2 (Hmgcs2)[24,25] gluta-
mate dehydrogenase (Gdh) [22], forkhead box O3a (Foxo3a) [24],
Ku70 [25], long chain acyl CoA dehydrogenase (Lcad) [23],
Serine/threonine protein kinase 11 (Stk11, or Lkb1) [26], and
mitochondrial ribosomal protein L10 (Mrpl10) [27], are all
activated when deacetylated by Sirt3. Of these proteins, we detect
acetylation of succinate dehydrogenase and malate dehydrogenase
in our data.
By integrating our GK and BN liver transcriptome and
acetylome analyses, we can predict the effects on the TCA cycle
(Figure 4). Malate dehydrogenase 1 (Mdh1), whose activity
increases with acetylation, is only acetylated in BN liver, so BN
Mdh1 activity is predicted to be higher than in GK. Succinate
dehydrogenase (Sdh; Complex II of oxidative phosphorylation) is
only acetylated in GK liver. Since Sdh activity decreases when it is
acetylated, we predict that GK Sdh activity is lower than in BN
[27]. Isocitrate dehydrogenase 2 and fumarate hydratase tran-
scripts are present at lower levels in GK than BN (though the
subunits of a-ketoglutarate dehydrogenase complex are equivocal).
Thus, the combined effect of lysine acetylation and transcript
differences increases flux through the TCA cycle, and which
should be higher in BN than GK liver.
Our results are consistent with a report showing that flux
through Complex II with palmitoylcarnitine substrate is reduced
in GK liver, but not in GK muscle [28]. We observe lower Sirt3
transcript abundance with concomitant increased Sdh acetylation
in liver, but no change of Sirt3 transcription in muscle.
Studies of liver mitochondrial energetics in GK rats have
demonstrated that the GK rat has a low endogenous ATP/ADP
ratio [29], which could be the result of reduced flux through the
TCA cycle. In the liver mitochondrial proteome, phosphopro-
teome and hydroxyproteome of GK rats, [30] suggest that protein
expression is coordinated between the TCA cycle, fatty acid
oxidation and oxidative phosphorylation during the progression
from pre-diabetes to early Type 2 diabetes. Here we show that GK
liver protein acetylation provides another layer post-translational
control of enzyme activity. It is important to note that acetylation
patterns in tissues other than liver are likely to be different [31].
We find that DNA variation in the Sirt3 promoter may
contribute to impaired glucose homeostasis in the GK model of
type 2 diabetes. Diabetes in the GK rat is a complex, multifactorial
disease, caused by susceptibility alleles isolated from an outbred
Figure 4. Lysine acetylation and mRNA expression in components of TCA cycle. Green arrow pointing up (next to malate dehydrogenase)
indicates acetylation causes increase in enzyme activity. Red arrow pointing down (next to isocitrate dehydrogenase and succinate dehydrogenase)
refers to decrease in enzyme activity with acetylation.
doi:10.1371/journal.pone.0094555.g004
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Wistar stock upon selection of glucose intolerant animals. The
polygenic threshold model for complex dichotomous conditions is
therefore likely to apply [32]. Under this model, contributing
factors accumulate until a threshold is reached, leading to descent
into disease. Other rat strains may have reduced Sirt3 deacetylase
activity, but are below the threshold required to move into the
disease state.
Our data also provide insights into the relationship between
glucose intolerance and ageing. Wistar-related rat strains have
shorter lifespans than BN rats [33]. Though there is some
controversy about the role of sirtuins in ageing, they do mediate
metabolic adaptation to stress and changes in nutrition [1] which
affect ageing, and higher levels of Sirt3 in BN rat may contribute to
its longer lifespan. Furthermore, higher Sirt3 in BN rat liver may
contribute to its resistance to the metabolic syndrome. Knockdown
of Sirt3 in the BN rat and measurement of its effects on metabolism
and longevity, could test this hypothesis.
Materials and Methods
Animals
GK, BN and congenic rat strains were provided from our
breeding colony at Biomedical Services, University of Oxford.
Rats were housed in groups of five per cage, with free access to
water and standard laboratory chow pellets (B&K Universal Ltd.,
Grimston, Aldbrough, Hull) and were maintained on a 12-h light-
dark cycle, at a room temperature of 21uC with a relative humidity
of 55610%. Tissues were collected from 7–8 month old animals
that were fasted overnight and killed by a rising concentration of
CO2. The tissue was flash-frozen and stored in a 280uC freezer
until protein or RNA isolation was performed. Records of the
breeding colony were kept using a FilemakerPro database [34].
Animal procedures were approved by the ethical review panel of
the University of Oxford and UK Home Office project licence
PPL 30/2918.
RNA preparation
Liver and brown adipose tissue (BAT) were taken from six each
of GK, BN.GK1consomic, and Brown Norway (BN control) male
rats and flash-frozen in liquid nitrogen. Tissue samples were
similarly taken from male BN.GK congenics derived for different
sections of GK rat chromosome 1 (four each of strains BN.GK1b,
1h, 1o) (Figure 1B, right).
Total RNA was isolated from frozen tissues using either the
RNeasyH kit (Qiagen, Crawley, UK), or Trizol reagent (Invitrogen
Life Technologies, Paisley, UK). Briefly, for RNeasy kit, frozen
tissue samples were homogenized in QIAzol Lysis Reagent using a
Qiagen TissueLyser. Following phase separation after addition of
chloroform, total RNA was purified using a spin technology
according to the manufacturer’s guidelines and eluted in RNase-
free water. RNA was isolated from some tissues using Trizol
reagent according to manufacturer’s protocol. RNA concentra-
tions were determined using a NanoDrop spectrophotometer and
RNA quality, purity and integrity were assessed using an Agilent
2100 Bioanalyser (Agilent Technologies, Waldbronn, Germany).
Illumina Bead Array hybridization and scanning
Gene transcription profiling for the BN, GK, and chromosome
1 congenic strains was performed using SentrixH BeadChip
RatRef-12 v1 Whole-Genome Gene Expression Arrays (Illumina
Inc., San Diego, California, USA).
Double-stranded cDNA and purified biotin-labeled cRNA were
synthesized from 300 ng high quality total RNA using the
IlluminaH TotalPrep RNA Amplification Kit (Ambion Inc.,
Austin, Texas, USA). cRNA concentrations were determined
using a NanoDrop spectrophotometer whilst cRNA quality and
integrity were assessed using an Agilent 2100 Bioanalyser (Agilent
Technologies, Waldbronn, Germany). Hybridizations onto Sen-
trixH BeadChip RatRef-12 v1 Arrays were carried out using
750 ng of each biotinylated cRNA in a 58uC hybridization oven
for 18 hours. Following washing and staining with Streptavidin-
Cy3, the BeadChip Arrays were scanned on the IlluminaH
BeadArray Reader (Illumina Inc., San Diego, USA). Resulting
data were then preliminarily analysed using the IlluminaH
BeadStudio Application software before undergoing comprehen-
sive statistical analysis.
Microarray experiments were compliant with MIAME (Mini-
mum Information About a Microarray Experiment) and both
protocol details and raw data have been deposited in ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) under the accession num-
ber E-MTAB-1048.
Statistical analysis of Illumina microarray data and Gene
Ontology annotation
Microarray data were imported and normalized using normexp
[35]. Batch effects on expression values, as revealed by a principal
component analysis, were dealt with by using the array identifier
as additive covariant in the linear model. Differentially expressed
genes were identified by comparing the 1consomic strain or GK
with the BN strain. A linear model was fitted using the software
LIMMA. Genes were tested for differential expression using a
moderated t-statistic. Multiple testing correction of p-values was
carried out using the false discovery rate [36].
Quantitative real-time PCR
Total RNA was treated with Turbo DNA-free DNase kit, for
removal of genomic DNA (Ambion Inc., Austin, Texas, USA).
First-strand cDNA synthesis was performed using Superscript III
First-strand Synthesis Supermix for qRT-PCR (Invitrogen, Pais-
ley, UK). Assays were performed on a Rotor-Gene 3000 system
(Corbett Research, Milton, UK) using the QuantiTect SYBR
Green PCR kit (Qiagen Ltd., Crawley, UK), with PCR primers as
listed in Table S1. Analysis was performed using the standard
curve method (Rotor-Gene Software 5.0.47; Corbett Research,
Milton, UK). Gene expression was normalized against the
expression of either actin or acidic ribosomal phosphoprotein P0
(36B4). Experiments were performed in triplicate with samples
prepared from 4–6 animals per group. Statistical significance was
determined by the two-tailed independent sample t-test or
univariate ANOVA, when testing more than two groups.
Sequencing of the Sirt3 gene and promoter cloning
Polymorphism information comparing GK and BN for the region
containing Sirt3 and the flanking 59 and 39 sequence was obtained
by comparing our genome sequence of the GK rat (Kaisaki,
unpublished) with the BN reference sequence. BN-GK SNPs in the
region of chr1:201019865-201045697 were submitted for analysis to
the online tool at Ensembl, Variant effect predictor (http://www.
ensembl.org/info/docs/variation/vep/index.html, [13]).
For cloning, the Sirt3 promoter region (RGSC3.4,
chr1:201,043,757-201,044,402) was amplified with the primers
Sirt3-promoter-F (59-ACACAAATACCAGGCAGTCG-39) and
Sirt3-promoter-R (59-ACCGTTGACAGCTTATCTGC-39) from
genomic DNA of either GK or BN rats, using proofreading
enzyme Phusion High Fidelity PCR mix (New England Biolabs,
Hitchin, UK), and ligated first into PCRII-TOPO vector
(Invitrogen, Paisley, UK) with Roche Rapid Ligation kit, and
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then subcloned into pGL3-basic Luciferase Reporter vector
(Promega, Southampton, UK). Clones were sequenced to confirm
there were no PCR errors.
Cell transfection and luciferase assay
HEP3B hepatoma and HEK293T cells were plated in 24-well
plates at 2.56104 cells/well, and transfected the next day using
Fugene 6, following manufacturer protocols (Roche Molecular
Biochemicals, Burgess Hill, UK). Two different concentrations of
pGL3-promoter plasmid were transfected, and pCMV-LacZ was co-
transfected in all cells (pCMV-LacZ was kindly provided by J.
Braganca and S. Bhattacharya). Luciferase activity was measured
using Promega Luciferase Assay System (Promega, Southampton,
UK), and read on a Labsystems Luminoskan Ascent microplate
luminometer (Thermo Fisher Scientific, Loughborough, UK).
Activity of b-galactosidase was assayed by measuring cleavage of
the substrate o-nitrophenyl-b-D-galactoside (ONPG) [37]. Two to
three independent transfection experiments were run, each time in
triplicate wells, and results are corrected for transfection efficiency by
expressing data as the ratio of luciferase to b-galactosidase activity.
Analysis of acetylated proteome
Protein extraction and trypsin digest. Detection of protein
acetylation was previously shown to be more optimal when the
enrichment step as performed at the peptide level [31,38]. Liver
tissue was homogenised in Lysis buffer, consisting of 50 mM Tris-
HCl, pH 7.4, 0.5% NP-40 substitute, 150 mM NaCl, 20 mM
MgCl2, 10 mM trichostatin A, 10 mM nicotinamide, 50 mM
butyric acid, and protease inhibitor cocktail (Pierce, Cramlington,
UK), using a Tissuelyser at 20 mHz for 3 min (Qiagen Ltd.,
Crawley, UK). Samples were rotated in a cold room for 30 min,
sonicated, and centrifuged 13000 rpm for 20 min at 4uC to
remove solids. Protein concentration was measured (Pierce BCA
protein assay kit, Perbio Science UK, Ltd, Cramlington, UK), and
30 mg of protein from each sample was methanol-chloroform
extracted [39]. The pellet was resuspended in 6 M urea in 0.1 M
Tris, pH 7.8 by vortexing and sonicating. The proteins were
reduced in 10 mM DTT, alkylated with 40 mM iodoacetamide,
and reduced again in 40 mM DTT. Urea concentration was
reduced to 0.7 M by diluting with water, then trypsin was added in
a 1:50 ratio (i.e. 60 mg trypsin for 30 mg protein), and incubated at
37uC overnight. Samples were desalted using Sep-pak C18
cartridges (Waters Ltd, Elstree, UK), then evaporated to dryness
in a speed-vac.
Immunoprecipitation of acetylated peptides. Pellets were
resuspended in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl,
1% NP-40 substitute (Sigma-Aldrich, Gillingham, UK), 0.25%
Na-deoxycholate, 1 mM EDTA), then diluted in NET buffer
(50 mM Tris, pH 7.4, 5 mM EDTA, 150 mM NaCl). The tryptic
peptides were cleared of non-specifically binding peptides by
incubating with Protein A-dynabeads (Invitrogen, Paisley, UK).
Immunoprecipitation was performed using a mixture of mouse
monoclonal and rabbit polyclonal pan-acetyllysine antibodies
(NEB Cell Signalling Technology, Hitchin, UK) conjugated to
Protein A-dynabeads in NET buffer. Beads were washed three
times with NET buffer, transferred to a fresh tube, and eluted
twice with ice-cold 100 ml elution buffer (100 mM glycine,
pH 2.5). Eluates were desalted using Supel-Tips C18 micropipette
tips (‘‘zip-tips’’, Sigma-Aldrich, Gillingham, UK), and evaporated
to dryness in a speed-vac.
LC-MS/MS Mass-spectrometric analysis. The analysis of
digested immunoprecipitated material was performed by LC-MS/
MS using an orbitrap Velos (Thermo) coupled to a nano-UPLC
system (NanoAcquity, Waters) using a reversed phase
75 mm6250 mm C18 column as described [39]. MS/MS spectra
were searched against the NCBInr Rodentia database
(v2012.07.08, 18970916 sequences) using the Mascot search
engine v2.3.01, allowing two missed cleavage and 20 ppm/
0.5 Da mass deviations in MS/MSMS, respectively. Carbamido-
methylation of cysteine was a fixed modification. Oxidation of
methionine, and acetylation of lysine were used as variable
modifications. Acetylated peptides were identified on a Mowse
score probability based scoring algorithm with a.95% confidence
of identification. Acetylated lysine residues were detected as
+42.01 Da mass tags and MS/MS spectra required at least four
consecutive b or y ions. Representative MS/MS spectra of acetyl-
lysine containing peptides are shown in Figure S2, and the peptide
scores for each acetylated peptide observed in either the GK or
BN samples were compared for an indication of a change in
relative abundance (Table S6).
RNA-sequencing
RNA-sequencing was performed according to standard operat-
ing procedures by the High-Throughput Genomics Group at the
Wellcome Trust Centre for Human Genetics. Briefly, mRNA was
selected from the total RNA, then fragmented and converted to
cDNA. The cDNA was end-repaired, A-tailed and adapter-ligated
before amplification and size selection. The prepared libraries
were multiplexed and quality controlled before 51-nt paired end
sequencing on an Illumina HiSeq2000 next generation sequencing
machine.
Sequencing reads were mapped to the rat reference genome
(RGSC3.4, Ensembl release 69) using tophat version 2.0.6 [40].
Bam files were filtered using samtools version 0.1.17 [41],
removing alignments with MAPQ ,15. Filtered Bam files were
sorted and duplicates were removed using samtools. Differential
expression was detected with edgeR [42]. Significant enrichment
of KEGG pathways was analysed with goseq [43].
Supporting Information
Figure S1 Luciferase reporter assays for transfection of
kidney cell line.
(PDF)
Figure S2 Mass spectrometry based detection of pro-
tein lysine acetylation.
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Table S1 Variant Effect Predictor for SNPs and indels
in the region of Sirt3.
(XLS)
Table S2 RNA-sequencing differentially expressed
genes in brown adipose tissue of GK and BN rats.
(XLS)
Table S3 RNA-sequencing differentially expressed
genes in liver of GK and BN rats.
(XLS)
Table S4 Significant enrichment of KEGG pathways in
brown adipose tissue.
(XLSX)
Table S5 Significant enrichment of KEGG pathways in
liver.
(XLSX)
Table S6 Acetylated peptides in GK and BN rat liver,
and their transcriptional expression.
(XLS)
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